High-throughput screening technologies such as mRNA expression microarrays were applied to find other molecular targets of selective COX2 inhibitors besides COX2, in order to discover the mechanisms explaining their anti-cancer effect in prostate cancer (John-Aryankalayil et al, 2009; Sooriakumaran et al, 2009) and CRC (Zagani et al, 2009). This evidence concerns the gene PTGS2 and Familial prostate cancer.